The global high performance medical plastics market size is projected to grow from USD 851 million in 2021 to USD 1,242 million by 2026, at a CAGR of 7.8% during the forecast period 2021 to 2026. Growing healthcare infrastructure in emerging economies and increasing instances of chronic diseases such as cancer and heart problems are expected to drive the medical devices market, which in turn, is likely to propel the demand for high performance medical plastics.
This growth can be attributed to the shift towards minimally invasive medical procedures, and an increase in demand for advanced medical technologies and devices across the globe. The development in patient-specific implants and 3D printed devices is expected to act as new opportunities for the high performance medical plastics market to grow. However, time consuming regulatory approval process is expected to hinder the market growth during the forecasted period.
Solvay SA (Belgium), SABIC (UAE), Mitsubishi Chemical Corporation (Japan), Evonik Industries AG (Germany), Arkema SA (France), Ensinger (Germany), Victrex PLC (UK), Rochling SE & Co. AG (Germany), Raumedic AG (Germany), The Chemours Company (US), DuPont (US), Saint-Gobain Performance Plastics (France), Celanese Corporation (US), Trelleborg (Sweden) and Tekni-Plex (US), among others are the key players operating in the high performance medical plastics market.
